Inventor
Alireza Rezania
Inventor
Hillsborough, NJ, US
Overview
Patents· 51 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes39%
A61KPreparations for medical, dental or toiletry purposes15%
C07KPeptides14%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations9%
A61LMethods or apparatus for sterilising materials or objects in general7%
A61FFilters implantable into blood vessels6%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
A61BDiagnosis2%
C08BPolysaccharides1%
PatentTitleYear
11,116,798Universal donor cells202111,116,797Universal donor cells202111,118,196Universal donor cells202111,118,195Universal donor cells202111,104,918Universal donor cells202111,008,587Universal donor cells202111,008,586Universal donor cells202110,947,511Differentiation of human embryonic stem cells into pancreatic endocrine cells using thyroid hormone and/or alk5, an inhibitor of tgf-beta type 1 receptor202110,870,832Use of small molecules to enhance MAFA expression in pancreatic endocrine cells202010,865,424Universal donor cells202010,724,052Universal donor cells202010,633,635Methods for production of functional beta cells202010,519,424Methods of enhancing expression of somatostatin in pancreatic endocrine cells201910,494,609Use of a TGF-bR-1 kinase to produce human pancreatic endocrine cells201910,420,803Differentiation of pluripotent stem cells to intestinal midgut endoderm cells201910,421,948Methods for making pancreatic endocrine cells201910,358,628Differentiation of human embryonic stem cells into single hormonal insulin positive cells201910,344,264Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells201910,329,534Methods for purifying cells derived from pluripotent stem cells201910,208,288Differentiation of human embryonic stem cells into pancreatic endocrine cells201910,138,465Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators201810,066,210Differentiation of human embryonic stem cells into pancreatic endocrine cells201810,006,006Use of small molecules to enhance MAFA expression in pancreatic endocrine cells20189,969,982Differentiation of human embryonic stem cells20189,969,981Methods for purifying cells derived from pluripotent stem cells20189,752,126'Differentiation of human pluripotent stem cells'20179,725,699'Differentiation of human embryonic stem cells'20179,593,307'Defined media for expansion and maintenance of pluripotent stem cells'20179,528,090'Differentiation of human embryonic stem cells'20169,458,430'Differentiation of pluripotent stem cells'20169,434,920'Defined media for expansion and maintenance of pluripotent stem cells'20169,388,386'Differentiation of human embryonic stem cells into single hormonal insulin positive cells'20169,388,387'Differentiation of human embryonic stem cells'20169,234,178'Differentiation of human pluripotent stem cells'20169,181,528'Differentiation of pluripotent stem cells'20159,062,290'Differentiation of human embryonic stem cells'20159,012,218'Differentiation of human embryonic stem cells'20158,778,673'Seeding cells on porous supports'20148,741,643'Differentiation of pluripotent stem cells to definitive endoderm lineage'20148,691,259'Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration'20148,366,787'Hybrid biologic-synthetic bioabsorbable scaffolds'2013RE043876'Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm'20128,017,395'Seeding cells on porous supports'20117,939,322'Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm'20117,914,808'Hybrid biologic/synthetic porous extracellular matrix scaffolds'20117,625,581'Tissue scaffolds for use in muscoloskeletal repairs'20097,192,604'Implantable biodegradable devices for musculoskeletal repair or regeneration'20077,091,191'Modified hyaluronic acid for use in musculoskeletal tissue repair'20066,884,428'Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration'20056,852,330'Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration'20056,599,323'Reinforced tissue implants and methods of manufacture and use'2003Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2003–2009Patents assigned to ETHICON INC (4)· patent assignee history
2003–2014Based in Hillsborough, NJ, US· patent location history
2011–2018Patents assigned to LIFESCAN INC (6)· patent assignee history
2012–2018Patents assigned to REZANIA ALIREZA (11)· patent assignee history
2015–2021Patents assigned to JANSSEN BIOTECH INC (25)· patent assignee history
2015–2021Based in Skillman, NJ, US· patent location history
2016–2019Based in Raritan, NJ, US· patent location history
2019–2020Based in San Diego, CA, US· patent location history
2020–2021Patents assigned to CRISPR THERAPEUTICS AG (9)· patent assignee history
2020–2021Based in Cambridge, MA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| JANSSEN BIOTECH INC | 25 | 2015–2021 |
| REZANIA ALIREZAself | 11 | 2012–2018 |
| CRISPR THERAPEUTICS AG | 9 | 2020–2021 |
| LIFESCAN INC | 6 | 2011–2018 |
| ETHICON INC | 4 | 2003–2009 |
Locations
| Location | Patents | Span |
|---|---|---|
| Hillsborough, New Jersey, US | 13 | 2003–2014 |
| Skillman, New Jersey, US | 12 | 2015–2021 |
| Cambridge, Massachusetts, US | 9 | 2020–2021 |
| Raritan, New Jersey, US | 8 | 2016–2019 |
| San Diego, California, US | 5 | 2019–2020 |